Maxid Pharma Consultancy Services Private Limited
About Maxid Pharma Consultancy Services Private Limited
Data last updated:
Maxid Pharma Consultancy Services Private Limited was a private limited company based in Pune, Maharashtra, India. The company has been struck off by the Registrar of Companies, typically due to non-filing of annual returns or failure to commence business. It is no longer operational and cannot enter into any legal contracts or agreements. It operated in the research and development sector. It was incorporated on 15 November 2016.
The company was registered with the Registrar of Companies (ROC), Pune, under CIN U74999PN2016PTC167135.
The company had an authorised share capital of ₹1 Lakh and a paid-up capital of ₹1 Lakh. It was led by directors Sagar Bhagawatrao Vidhate and Vyankatesh Mahadeorao Potey.
Its last annual general meeting (AGM) was held on 31 December 2020, and its latest financial statements are for the year ended 31 March 2020. The registered office was at S No 589/B Pl 59 Fl No 6 Gujrathwala Col. Bibwewadi, Pune, Maharashtra, India – 411037.
As per the financials filed for FY 2020, the company reported a revenue of ₹30,000, a decline of 93% compared to the previous year. For the same year it recorded a net loss of ₹61,148 (net margin -203.8%) and EBITDA of -₹31,961 (EBITDA margin -106.5%). Revenue has declined at a compounded annual rate (CAGR) of 32% over three years.
Company details
Contact details
Maxid Pharma Consultancy Services Private Limited's registered office is in Pune, Maharashtra. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Registered AddressS No 589/B Pl 59 Fl No 6 Gujrathwala Col. Bibwewadi, Pune, Maharashtra, India – 411037
- IndustryResearch & Development, Research & Development
To see the full contact details of Maxid Pharma Consultancy Services Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activity of Maxid Pharma Consultancy Services is professional, scientific and technical. In detail, this covers scientific research and development.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| M | Professional, Scientific and Technical | M5 | Scientific research and development |
To see the full business activity and turnover split of Maxid Pharma Consultancy Services Private Limited, buy the company report.
Financials of Maxid Pharma Consultancy Services Private Limited
FY 2020 filings availableMaxid Pharma Consultancy Services Private Limited reported revenue of ₹30,000 (down 93% YoY) for FY 2020.
Compounded Annual Growth Rate (CAGR)
Revenue has declined at a compounded annual rate (CAGR) of 32% over three years, including a 93% fall in the latest year. EBITDA fell 137% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2019-20 | FY 2018-19 | FY 2017-18 | FY 2016-17 |
|---|---|---|---|---|
| Profit and Loss Statement | ||||
| Revenue from Operations | ||||
| Other Income | ||||
| Total Revenue | ||||
| Cost of Materials Consumed | ||||
| Employee Benefit Expense | ||||
| Finance Costs | ||||
| Depreciation and Amortisation | ||||
| Other Expenses | ||||
| Total Expenses | ||||
| EBITDA | -₹31,961 | |||
| Profit Before Tax | ||||
| Tax Expense | ||||
| Net Profit (PAT) | -₹61,148 | |||
| Balance Sheet | ||||
| Share Capital | ||||
| Reserves and Surplus | ||||
| Net Worth (Total Equity) | ||||
| Long-term Borrowings | ||||
| Short-term Borrowings | ||||
| Trade Payables | ||||
| Total Liabilities | ||||
| Fixed Assets | ||||
| Investments | ||||
| Inventories | ||||
| Trade Receivables | ||||
| Cash and Bank Balance | ||||
| Total Assets | ||||
Financial Ratios
| Metrics | FY 2019-20 | FY 2018-19 | FY 2017-18 | FY 2016-17 |
|---|---|---|---|---|
| Profitability | ||||
| EBITDA Margin | -106.5% | |||
| Net Profit Margin | -203.8% | |||
| Return on Equity (ROE) | ||||
| Return on Capital Employed (ROCE) | ||||
| Return on Assets (ROA) | ||||
| Liquidity and Debt | ||||
| Current Ratio | ||||
| Quick Ratio | ||||
| Debt-to-Equity Ratio | ||||
| Interest Coverage Ratio | ||||
| Efficiency and Growth | ||||
| Asset Turnover | ||||
| Receivable Days | ||||
| Payable Days | ||||
| Inventory Days | ||||
| Revenue Growth | ||||
| Net Profit Growth | ||||
To see the full financial statements and ratios of Maxid Pharma Consultancy Services Private Limited, buy the company report.
Board of directors of Maxid Pharma Consultancy Services Private Limited
Maxid Pharma Consultancy Services has 2 current directors and 4 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Sagar Bhagawatrao Vidhate | Director | 01 Sep 2017 | 9 Years 1 Months | As last reported |
| Vyankatesh Mahadeorao Potey | Director | 01 Sep 2017 | 9 Years 1 Months | As last reported |
Peer comparison
Maxid Pharma Consultancy Services Private Limited is compared with the 10 companies closest to it by revenue in the same principal business activity (scientific research and development), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Natureka Green Technologies Private Limited | ₹31,660 (FY 2025) | -99.0% | Payyalore, Kerala, India | |||
| Innovora Biotech Private Limited | ₹31,200 (FY 2025) | 25.0% | Burdwan, West Bengal, India | |||
| Isert Foundation | ₹30,715 (FY 2024) | -83.0% | Aligarh, Uttar Pradesh, India | |||
| Castle Advanced Technologies and Systems Private Limited | ₹30,661 (FY 2025) | 121.0% | Nashik, Maharashtra, India | |||
| T-3 Molecular Genetics (T-3 Mgen) Private Limited | ₹30,060 (FY 2023) | -60.0% | Bangakore, Karnataka, India | |||
| Maxid Pharma Consultancy Services Private Limitedthis company | ₹30,000 (FY 2020) | -₹61,148 | -203.8% | -93.0% | Pune, Maharashtra, India | |
| Gayatri Devi Institute of Medical Science Private Limited | ₹30,000 (FY 2025) | -17.0% | Kharsia, Chhattisgarh, India | |||
| Sahasrara Digitech Private Limited | ₹29,000 (FY 2025) | Raipur, Chhattisgarh, India | ||||
| Jay Robotix Learning India Private Limited | ₹28,801 (FY 2024) | -79.0% | Sangareddy, Telangana, India | |||
| Biosia-Innovation (OPC) Private Limited | ₹28,563 (FY 2025) | 7.0% | Jammu, Jammu and Kashmir, India | |||
| Onco-Vac Biopharma Private Limited | ₹28,383 (FY 2025) | -98.0% | Delhi, India |
To see the full peer comparison of Maxid Pharma Consultancy Services Private Limited, buy the company report.
Auditor
Maxid Pharma Consultancy Services Private Limited is audited by AMITGOVINDMALU for the financial year 2017.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| AMITGOVINDMALU | FY 2017 | 158688 |
Shareholding
The shareholding of Maxid Pharma Consultancy Services Private Limited is on record for FY 2017, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2017 |
|---|---|
| Promoters | |
| Domestic institutional investors (DII) | |
| Foreign institutional investors (FII) | |
| Public | |
| Others |
To see the full shareholding pattern of Maxid Pharma Consultancy Services Private Limited, buy the company report.
Legal cases
No court or tribunal cases involving Maxid Pharma Consultancy Services Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Maxid Pharma Consultancy Services Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
No GST registration is on our record for Maxid Pharma Consultancy Services Private Limited; the GSTIN and return-filing check is in the company report Buy the company report.
Recent activity
Maxid Pharma Consultancy Services Private Limited has 6 board changes on record since 2017: 2 appointments and 4 cessations. The latest: Anirudha Vyankatesh Potey ceased to be Director on 07 Oct 2017.
Frequently asked questions
Maxid Pharma Consultancy Services has a status of "Struck Off" as per MCA records. This means the company has been officially removed from the Register of Companies, typically due to non-filing of annual returns or failure to commence business within one year of incorporation. A struck-off company cannot enter into any legal contracts or agreements, and any dealings with such an entity carry significant legal and financial risk.
Maxid Pharma Consultancy Services was a private limited company based in Pune, Maharashtra, India. The company worked in the research and development industry. It was incorporated on 15 November 2016 and is registered under CIN U74999PN2016PTC167135. The company has been struck off by the Registrar of Companies and is no longer operational.
Maxid Pharma Consultancy Services had 2 directors:
- Sagar Bhagawatrao Vidhate - Director
- Vyankatesh Mahadeorao Potey - Director
The CIN (Corporate Identification Number) of Maxid Pharma Consultancy Services is U74999PN2016PTC167135. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
The registered office of Maxid Pharma Consultancy Services is at S No 589B Pl 59 Fl No 6 Gujrathwala Col. Bibwewadi, Pune, Maharashtra, India – 411037.
Maxid Pharma Consultancy Services was incorporated on 15 November 2016. It is registered with the Registrar of Companies, Pune.
The latest financial statements of Maxid Pharma Consultancy Services on record with the MCA are for the year ended 31 March 2020. Its last annual general meeting was held on 31 December 2020. Year-wise statements from FY 2017 are in the company report.
Maxid Pharma Consultancy Services operated in the research and development industry. It worked in this industry before it was struck off.
The peers of Maxid Pharma Consultancy Services by revenue are Natureka Green Technologies Private Limited, Innovora Biotech Private Limited, Isert Foundation, Castle Advanced Technologies and Systems Private Limited, T-3 Molecular Genetics (T-3 Mgen) Private Limited and 5 more, all in the same principal business activity (scientific research and development).
Anirudha Vyankatesh Potey ceased to be Director on 07 Oct 2017. Kshama Bhagawatrao Vidhate ceased to be Director on 07 Oct 2017. Sagar Bhagawatrao Vidhate ceased to be Additional Director on 05 Oct 2017. Maxid Pharma Consultancy Services has 6 board changes on record in total.
The compliance status of Maxid Pharma Consultancy Services is compliant as of 21 July 2026.